期刊
JOURNAL OF THE NEUROLOGICAL SCIENCES
卷 267, 期 1-2, 页码 174-176出版社
ELSEVIER
DOI: 10.1016/j.jns.2007.10.008
关键词
ataxia; idebenone; clinical trial; cerebellum
资金
- NINDS NIH HHS [R56 NS045986-05, R56 NS045986] Funding Source: Medline
Many antioxidants have been suggested as potential treatments for Friedreich ataxia, but have not been tested in clinical trials. We found that a majority of patients in our cohort already use such antioxidants, including idebenone, which is not available at a pharmaceutical grade in the United States. Younger age, cardiomyopathy and shorter GAA repeat length were independent predictors of idebenone use, but no factors predicted use of other antioxidants. This confirms that non-prescription antioxidant use represents a major confounder to formal trials of existing and novel agents for Friedreich ataxia. (c) 2007 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据